Strata Critical Medical, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2026

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.





	Level	March 31, 2026		December 31, 2025
Assets
Money market fund (1)	1	$	51,787	$	23,111
Contingent consideration asset related to sale of business (2)	3	28,820		27,700
Indemnity holdback related to sale of business (2)	3	8,801		8,700
Total assets at fair value		$	89,408	$	59,511

Liabilities
Warrant liabilities - Public Warrants	1	$	46	$	990
Warrant liabilities - Private Warrants	2	25		540
Share-based payment liability-classified related to sale of business (3)	3	12,983		15,138
Equity consideration in escrow and contingent consideration - Keystone acquisition (4)	3	9,004		9,072
Total liabilities at fair value		$	22,058	$	25,740

(1) As of March 31, 2026 and 2025, the Company had cash equivalents held in a money market fund. The Company has concluded that due to the highly liquid nature of the fund, the carrying value approximates fair value, which represents a Level 1 input. The balance of cash equivalents held in the money market fund is included in cash and cash equivalents.

(2) Contingent consideration and indemnity holdback related to sale of the Passenger business are presented within “Prepaid expenses and other current assets” and “Other non-current asset”, respectively, on the unaudited interim condensed consolidated balance sheets.

(3) Share-based payment liability-classified related to the sale of the Passenger business is presented within “Other non-current liabilities” on the unaudited interim condensed consolidated balance sheets.
(4) Equity consideration in escrow and contingent consideration related to the Keystone acquisition are presented under “Accounts payable and accrued expenses” and “Other non-current liabilities” as applicable.

There were no transfers between levels of the fair value hierarchy during the three months ended March 31, 2026.

Summary of Change in Fair Value of Warrant Liabilities and Level 3 Assets and Liabilities

The following table presents the changes in fair value of the warrant liabilities:


	Public Warrants		Private Placement Warrants		Total Warrant Liability


Fair value as of January 1, 2026	$	990	$	540	$	1,530

Change in fair value of warrant liabilities	(944)		(515)		(1,459)
Fair value as of March 31, 2026	$	46	$	25	$	71

The following table presents the changes in fair value of the Level 3 assets for the three months ended March 31, 2026:


	Contingent Consideration asset		Indemnity Holdback		Total


Fair value as of January 1, 2026	$	27,700	$	8,700	$	36,400

Change in fair value	1,120		101		1,221
Fair value as of March 31, 2026	$	28,820	$	8,801	$	37,621

The following table presents the changes in fair value of the Level 3 liabilities for the three months ended March 31, 2026:


	Share-Based Payment Liability		Equity Consideration in Escrow and Contingent Consideration - Keystone		Total


Fair value as of January 1, 2026	$	15,138	$	9,072	$	24,210

Change in fair value	(2,155)		(68)		(2,223)
Fair value as of March 31, 2026	$	12,983	$	9,004	$	21,987